Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma
The transcriptomic atlas provided a valuable resource for deciphering the intra-tumoral heterogeneity in PDAC and uncovered a connection between tumor intrinsic transcriptional state and T cell activation, suggesting potential biomarkers for anticancer treatment such as targeted therapy and immunotherapy. Expand
Surgical management of patients with insulinomas: Result of 292 cases in a single institution
There are few large sample, single‐center series that focus on the surgical management strategy of insulinomas, and this work aims to be the first to provide a systematic literature review of this strategy. Expand
Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.
Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis, chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells. Expand
Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.
Data indicated that administration of salinomycin, which targets CSCs, may constitute a potential therapeutic strategy for improving the efficacy of gemcitabine to eradicate pancreatic cancer. Expand
68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake
- Yaping Luo, M. Yu, +7 authors Yupei Zhao
- European Journal of Nuclear Medicine and…
- 1 March 2015
This work presents the first successful use of Ga-NOTA-exendin-4 PET/ CT for the identification of an occult insulinoma that could not be detected by other standard imaging methods. Expand
Robotic versus Open Pancreatectomy: A Systematic Review and Meta-analysis
The results of this meta-analysis suggest that robotic pancreatectomy is as safe and efficient as, if not superior to, open surgery for patients with benign or malignant pancreatic diseases, however, the evidence is limited and more randomized controlled trials are needed. Expand
Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells.
- L. You, D. Chang, Hongzhen Du, Yupei Zhao
- Biology, Medicine
- Biochemical and biophysical research…
- 1 April 2011
The results identified PVT1 as a regulator of Gemcitabine sensitivity in pancreatic cancer cells and validated the genome-wide and piggyBac transposon-based genetic screening platform for the identification of genetic determinants as well as potential biomarkers for the rational design of Gem citabine chemotherapies for pancreatic cancers. Expand
Tumor microenvironment participates in metastasis of pancreatic cancer
This review discusses how the pancreatic cancer microenvironment participates in metastasis, representing a potential target for combination therapy to enhance overall survival. Expand
PD-1/PD-L1 and immunotherapy for pancreatic cancer.
In this review, the development and limitations of anti-PD-1/PD-L1 monotherapy in pancreatic cancer are discussed, the underlying mechanism is considered, combination strategies overcoming resistance to anti- PD-1 /PD- L1 immunotherapy, and the prospect of targeting PD- 1/PD/L1 for the immunotherapy of pancreatic cancers is considered. Expand
5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers
5hmC-based biomarkers of circulating cfDNA were highly predictive of colorectal and gastric cancers and were superior to conventional biomarkers and comparable to 5hmC biomarkers from tissue biopsies, which could lead to the development of effective, minimally invasive methods for diagnosis and prognosis of cancer from the analyses of blood samples. Expand